ARDS - アリディス・ファ―マシュ―ティカルズ (Aridis Pharmaceuticals Inc.) アリディス・ファ―マシュ―ティカルズ

 ARDSのチャート


 ARDSの企業情報

symbol ARDS
会社名 Aridis Pharmaceuticals Inc (アリディス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Aridis Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies such as rise in drug resistance short duration of response negative impact on the human microbiome and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections primarily hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Its lead product candidate AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M mAb targeting P. aeruginosa serotype O11.   アリディス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、感染症に対する免疫療法の開発・商業化に従事する。完全ヒトモノクロナ―ル抗体を用いて、薬物耐性や短い薬効時間、ヒトのミクロバイオ―ムへの悪影響などの治療の欠点を克服するように設計され、同社の差別化抗体発見プラットフォ―ムを使用する。本社所在地はカリフォルニア州サンノゼ。   Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.
本社所在地 5941 Optical Ct. San Jose CA 95138 USA
代表者氏名
代表者役職名
電話番号 +1 408-385-1742
設立年月日 2003年
市場名 NASDAQ Small Cap
ipoyear 2018年
従業員数 30人
url www.aridispharma.com
nasdaq_url https://www.nasdaq.com/symbol/ards
adr_tso
EBITDA EBITDA(百万ドル) -21.68200
終値(lastsale) 12.8254
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 100.48690
売上高 売上高(百万ドル) 1.16000
企業価値(EV) 企業価値(EV)(百万ドル) 161.21890
当期純利益 当期純利益(百万ドル) -22.02800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aridis Pharmaceuticals Inc revenues increased from $44K to $344K. Net loss applicable to common stockholders decreased 35% to $10.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Change in fair value of warrant liabilit increase from $4.6M (expense) to $3M (income).

 ARDSのテクニカル分析


 ARDSのニュース

   Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel  2020/10/27 09:30:00 PR Newswire
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH…
   Aridis Pharmaceuticals (NASDAQ:ARDS) Stock Rating Lowered by Zacks Investment Research  2020/10/21 17:08:41 The Olympia Report
Aridis Pharmaceuticals (NASDAQ:ARDS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to […]
   Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering  2020/10/14 09:30:00 PR Newswire
SAN JOSE, Calif., Oct. 14, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered…
   Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501  2020/09/08 09:30:00 PR Newswire
SAN JOSE, Calif., Sept. 8, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced it has reached an agreement with the US…
   Aridis Pharmaceuticals to Present at Upcoming Investor Conferences  2020/09/04 17:32:00 PR Newswire
SAN JOSE, Calif., Sept. 4, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today announced that Vu Truong, Ph.D., Chief…
   Aridis Pharmaceuticals (NASDAQ:ARDS) Stock Rating Lowered by Zacks Investment Research  2020/10/21 17:08:41 The Olympia Report
Aridis Pharmaceuticals (NASDAQ:ARDS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to […]
   Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering  2020/10/14 09:30:00 PR Newswire
SAN JOSE, Calif., Oct. 14, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered…
   Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501  2020/09/08 09:30:00 PR Newswire
SAN JOSE, Calif., Sept. 8, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced it has reached an agreement with the US…
   Aridis Pharmaceuticals to Present at Upcoming Investor Conferences  2020/09/04 17:32:00 PR Newswire
SAN JOSE, Calif., Sept. 4, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today announced that Vu Truong, Ph.D., Chief…
   Mesoblast (ASX:MSB) receives ethics approval to treat Covid-19 patients  2020/09/02 01:41:00 Finance News Network
02 Sep 2020 - Mesoblast (ASX:MSB) today announced that it has received ethics approval to include Australian hospitals in the controlled trial of remestemcel-L Covid-19 patients with acute respiratory distress syndrome (ARDS).
   9 Meters Biopharma : Announces Issuance of Patent for Use of Larazotide in Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS)  2020/07/28 11:36:12 MarketScreener
9 Meters Biopharma, Inc. Announces Issuance of Patent for Use of Larazotide in Acute Lung Injury and Acute Respiratory Distress Syndrome July 28, 2020 …
   Almost 5% people with mild Covid-19 progress to severe form: Study  2020/07/18 13:54:29 Sify.com
London, July 18 (IANS) Researchers have found that approximately 5 per cent of people with Covid-19 progress to a severe or critical form, including development of severe pneumonia which leads to acute respiratory distress syndrome (ARDS). ARDS is a type of respiratory failure characterised by rapid onset of widespread inflammation in the lungs. Its symptoms include shortness of breath, rapid breathing and bluish skin colouration. While these forms sometimes occur early in the course of the disease, clinical observations generally describe a two-stage progression of the disease, beginning with a mild to moderate form, followed by respiratory aggravation 9 to 12 days after the onset of the first symptom. A growing number of indications suggest that this aggravation is caused by a large increase in cytokines -- a large group of proteins, peptides or glycoproteins that are secreted by specific cells of the immune system. "This runaway inflammatory response is correlated with massive infiltration in the lungs of innate immune cells, namely neutrophils and monocytes, creating lung damage and ARDS," wrote the study authors from the Inserm Research Institute in France.
   DSG Supports PhaseBio Pharmaceuticals with Unified Clinical Trial Software Platform for COVID-19 Trial  2020/07/17 13:30:00 Business Wire
MALVERN, Pa.--(BUSINESS WIRE)--DSG, Inc., a global leader of eClinical software solutions and services for the life sciences industry has successfully launched a COVID-19 study with PhaseBio Pharmaceuticals for its potentially pivotal clinical trial evaluating PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS). Understanding the urgent nature and the challenges faced by physicians looking
   Endpoint Health Launches with Mission to Bring Life-Saving Targeted Therapies to Patients with Critical Illnesses  2020/07/13 12:10:00 Business Wire
PALO ALTO, Calif.--(BUSINESS WIRE)--Endpoint Health launched today on a mission to bring life-saving targeted therapies to patients with critical illnesses including sepsis and acute respiratory distress syndrome (ARDS) — life-threatening conditions often caused by serious infections, including COVID-19. The first targeted therapeutics company focused on integrated solutions for critical illnesses, Endpoint Health’s mission is to combine novel and on-market therapeutics, companion diagnostics a
   Acute Respiratory Distress Syndrome (ARDS) Epidemiology 2017-2030 - ResearchAndMarkets.com  2020/07/13 11:39:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Acute Respiratory Distress Syndrome (ARDS) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of the disease, historical and forecasted Acute Respiratory Distress Syndrome (ARDS) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. Epidemiology Perspective The disease epidemiology covered in the report provides historical as well

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アリディス・ファ―マシュ―ティカルズ ARDS Aridis Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)